Heron Therapeutics Inc vs Western Union Co — how do they compare? Heron Therapeutics Inc trades at $0.32 (market cap $63.41M), while Western Union Co trades at $7.05 (market cap $2.19B). The key difference: Western Union Co is far larger — about 34.5× Heron Therapeutics Inc's market cap, and Western Union Co pays a 13.37% dividend while Heron Therapeutics Inc pays none. Which is the better fit depends on your goals.
| HRTX | WU | |
|---|---|---|
Market Cap | $63.41M | $2.19B |
Sector | Health | Technology |
52-Week High | $1.49 | $10.28 |
52-Week Low | $0.32 | $6.36 |
Enterprise Value | $161.31M | $2.10B |
Dividend Yield | — | 13.37% |
Signals from Pluang's Aura AI — not financial advice
Heron Therapeutics (HRTX) trades at $0.49, down 1.64% today, with a bearish technical signal from moving averages. The company reported Q2 2026 revenue of $37.7M but missed earnings expectations with a $0.03 loss per share. Despite negative net income margins, HRTX maintains strong analyst support with 94.7% buy ratings. Recent news highlights patent litigation developments and quarterly earnings underperformance.
HRTX faces significant fundamental challenges with persistent losses and declining revenue projections, though analyst consensus remains overwhelmingly bullish. Investment opportunity exists if the company can achieve profitability and meet growth targets, but risks include ongoing operational losses, competitive pressures, and execution challenges in the biotechnology sector.
Western Union (WU) trades at $7.08, down 1.12% today, with a bearish technical signal and recent earnings misses in Q1 and Q2 2026. Valuation ratios appear attractive with a P/E of 5.71 and P/S of 0.56, but revenue has declined from $4.5B in 2022 to $4.05B in 2025. The company maintains a strong dividend yield, paying $0.24 quarterly, and recently launched Stablecard with Rain to expand digital services.
The outlook is cautious due to earnings volatility and competitive pressures in money transfers. Opportunities include cost management and digital growth, but risks from declining retail performance and high debt levels persist. Analyst consensus is mixed with a $7.14 price target, reflecting uncertainty over turnaround efforts.
Trailing returns across standard periods
Latest headlines on both assets
Heron Therapeutics is a commercial-stage biotechnology company focused on improving patient care. It develops best-in-class medicines for pain management and cancer care to address unmet medical needs.
Read more on HRTX →Western Union provides domestic and international money transfers through its global network of about 500,000 outside agents. It is the largest money transfer company in the world and one of only a few companies with a truly global agent network.
Read more on WU →